Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Investigating the Metabolic Effects of Oncolytic Virus derived Type I Interferon on CAR-T cells
EF 2022-23
Résumé
Cancer immunotherapy is a type of cancer treatment that uses a patient's own immune system to fight cancer. T cells are an immune cell that are capable of killing cancer cells. Chimeric antigen receptor (CAR) T cell therapy is a commonly used immunotherapy where T cells are isolated from a patient's blood, modified in a lab to enable them to target cancer cells, and then infused back into the patient where they can kill their tumours. While these cells are good against liquid tumours, they have a hard time penetrating and killing solid tumours. So, oncolytic viruses are often used in combination with CAR T cells. Oncolytic viruses are viruses that can kill cancer cells. In doing so, they cause the cancer cells to release inflammatory signals, which helps CAR T cells find and penetrate solid tumours. However, when oncolytic viruses infect cells, the infected cells secrete an antiviral molecule called type I interferon. Type I interferon has been shown to be harmful to CAR T cells, and cause them to die off before reaching the tumour. My hypothesis is that type I interferon is harmful to these cells because it changes their metabolism - how they make and use energy. My goal is to investigate how type I interferon changes the metabolism of CAR T cells, and how we can modify the cells to make them resistant to these changes.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486382
Name
Ishak Mira
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Metabolic Effects of Oncolytic Virus derived Type I Interferon on CAR-T cells
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adoptive T Cell Therapy; Cancer Immunotherapy; Car T Cell; Immunology; Immunometabolism; Interferon; Metabolism; Oncolytic Virus Vaccines; Single Cell Sequencing; T Cell Exhaustion
Abstract
Cancer immunotherapy is a type of cancer treatment that uses a patient's own immune system to fight cancer. T cells are an immune cell that are capable of killing cancer cells. Chimeric antigen receptor (CAR) T cell therapy is a commonly used immunotherapy where T cells are isolated from a patient's blood, modified in a lab to enable them to target cancer cells, and then infused back into the patient where they can kill their tumours. While these cells are good against liquid tumours, they have a hard time penetrating and killing solid tumours. So, oncolytic viruses are often used in combination with CAR T cells. Oncolytic viruses are viruses that can kill cancer cells. In doing so, they cause the cancer cells to release inflammatory signals, which helps CAR T cells find and penetrate solid tumours. However, when oncolytic viruses infect cells, the infected cells secrete an antiviral molecule called type I interferon. Type I interferon has been shown to be harmful to CAR T cells, and cause them to die off before reaching the tumour. My hypothesis is that type I interferon is harmful to these cells because it changes their metabolism - how they make and use energy. My goal is to investigate how type I interferon changes the metabolism of CAR T cells, and how we can modify the cells to make them resistant to these changes.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ishak, Mira
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~